Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Carboplatin 28Cisplatin 25pembrolizumab 25Paclitaxel 22Nivolumab 20Gemcitabine 17Pemetrexed 15Rituximab 14Ipilimumab 13Cyclophosphamide 11Dexamethasone 11Fluorouracil 10durvalumab 10Capecitabine 9Docetaxel 9trastuzumab deruxtecan 9Lenalidomide 8Oxaliplatin 8atezolizumab 8Doxorubicin 7daratumumab 7osimertinib 7Bortezomib 6Cytarabine 6Leucovorin 6Sunitinib 6Trastuzumab 6olaparib 6venetoclax 6130-nm albumin-bound paclitaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × luprolide acetate gel depot × 1 year × Clear all
NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Pfizer

Phase 3 Active not recruiting
1,068 enrolled 20 charts 1 FDA
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡